MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2023.12.011

Медицинская библиотека · Vaccine · 2023

Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.

Park Sang-In, Park Sohyun, Lee Kunse, Kwak Hye Won, Kim Yong Kwan, Park Hyeong-Jun, Bang Yoo-Jin, Kim Jae-Yong, Kim Daegeun, Seo Ki-Weon, Lee Su Jeen, Kim Hun, Kim Yeonhwa, Kim Do-Hyung, Park Hyo-Jung, Jung Seo-Yeon, Ga Eulhae, Hwang Jaehyun, Na Woonsung, Hong So-Hee, Lee Sang-Myeong, Nam Jae-Hwan

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

As the nasal mucosa is the initial site of infection for COVID-19, intranasal vaccines are more favorable than conventional vaccines. In recent clinical studies, intranasal immunization has been shown to generate higher neutralizing antibodies; however, there is a lack of evidence on sterilizing immunity in the upper airway. Previously, we developed a recombinant measles virus encoding the spike protein of SARS-CoV-2 (rMeV-S), eliciting humoral and cellular immune responses against SARS-CoV-2.

OBJECTIVES

In this study, we aim to provide an experiment on nasal vaccines focusing on a measles virus platform as well as injection routes.

STUDY

DESIGN

Recombinant measles viruses expressing rMeV-S were prepared, and 5 × 105 PFUs of rMeV-S were administered to Syrian golden hamsters via intramuscular or intranasal injection. Subsequently, the hamsters were challenged with inoculations of 1 × 105 PFUs of SARS-CoV-2 and euthanized 4 days post-infection. Neutralizing antibodies and RBD-specific IgG in the serum and RBD-specific IgA in the bronchoalveolar lavage fluid (BALF) were measured, and SARS-CoV-2 clearance capacity was determined via quantitative reverse-transcription PCR (qRT-PCR) analysis and viral titer measurement in the upper respiratory tract and lungs. Immunohistochemistry and histopathological examinations of lung samples from experimental hamsters were conducted.

RESULTS

The intranasal immunization of rMeV-S elicits protective immune responses and alleviates virus-induced pathophysiology, such as body weight reduction and lung weight increase in hamsters. Furthermore, lung immunohistochemistry demonstrated that intranasal rMeV-S immunization induces effective SARS-CoV-2 clearance that correlates with viral RNA content, as determined by qRT-PCR, in the lung and nasal wash samples, SARS-CoV-2 viral titers in lung, nasal wash, BALF samples, serum RBD-specific IgG concentration, and RBD-specific IgA concentration in the BALF.

CONCLUSION

An intranasal vaccine based on the measles virus platform is a promising strategy owing to the typical route of infection of the virus, the ease of administration of the vaccine, and the strong immune response it elicits.

Для цитирования: Park Sang-In, Park Sohyun, Lee Kunse, Kwak Hye Won, Kim Yong Kwan, Park Hyeong-Jun, Bang Yoo-Jin, Kim Jae-Yong, Kim Daegeun, Seo Ki-Weon, Lee Su Jeen, Kim Hun, Kim Yeonhwa, Kim Do-Hyung, Park Hyo-Jung, Jung Seo-Yeon, Ga Eulhae, Hwang Jaehyun, Na Woonsung, Hong So-Hee, Lee Sang-Myeong, Nam Jae-Hwan. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.. Vaccine. 2023. DOI: 10.1016/j.vaccine.2023.12.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.